Milan, Lombardy, Italy Genextra appeared to be the Corporate Investor, which was created in 2003. The venture was found in Europe in Italy. The leading representative office of defined Corporate Investor is situated in the Milan.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Biotechnology. The fund has specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Erydel, Intercept Pharmaceuticals. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Italy.
Comparing to the other companies, this Genextra performs on 4 percentage points more the average number of lead investments. The high activity for fund was in 2018. The increased amount of exits for fund were in 2012. The fund is constantly included in less than 2 investment rounds annually. Considering the real fund results, this Corporate Investor is 47 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars.
The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Genextra, startups are often financed by Innogest Capital, FM Management. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Innogest Capital. In the next rounds fund is usually obtained by OrbiMed.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Carl Zeiss Meditec | Germany, Jena, Thuringen |
| Chunde Touzi | China, Shanghai |
| Junglee | California, Sunnyvale, United States |
| marquee angels | - |
| Otto Capital | Seattle, United States, Washington |
| Qingzhe Capital | - |
| Realtime ventures LLP | Gurgaon, Haryana, India |
| The Untitled Venture Company | California, San Francisco, United States |
| Volkswagen Financial Services | Herndon, United States, Virginia |
| Yunlin | China, Jiading District |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
InnovHeart | $55M | 27 Jan 2022 | Milan, Lombardy, Italy | ||
InnovHeart | $23M | 07 Aug 2020 | Italy, Lombardy | ||
Erydel | $31M | 24 Apr 2018 | Campobasso, Molise, Italy | ||
Erydel | $17M | 01 Jul 2013 | Campobasso, Molise, Italy | ||
Intercept Pharmaceuticals | $30M | 10 Aug 2012 | New York, New York, United States | ||
Intercept Pharmaceuticals | $25M | 25 Jan 2010 | New York, New York, United States | ||
Intercept Pharmaceuticals | $25M | 29 Jul 2008 | New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
InnovHeart | $55M | 27 Jan 2022 | Milan, Lombardy, Italy | ||
InnovHeart | $23M | 07 Aug 2020 | Italy, Lombardy | ||
Erydel | $31M | 24 Apr 2018 | Campobasso, Molise, Italy | ||
Erydel | $17M | 01 Jul 2013 | Campobasso, Molise, Italy | ||
Intercept Pharmaceuticals | $30M | 10 Aug 2012 | New York, New York, United States | ||
Intercept Pharmaceuticals | $25M | 25 Jan 2010 | New York, New York, United States | ||
Intercept Pharmaceuticals | $25M | 29 Jul 2008 | New York, United States |
